ASTP Finalizes Scaled-Back HTI-2 Rule
Although proposed rule was wide-ranging, the final rule, which will be published on Dec. 16, contained only TEFCA-related items
Read More
Value-Based Care Is a Four Layer Cake — Why Do We Only Focus on The Icing?
During a recent panel discussion, three healthcare experts discussed reasons why value-based care is struggling to reach scale. The post Value-Based Care Is a Four Layer Cake — Why Do We Only Focus on The Icing? appeared first on MedCity News.
Public Health Risks of Urban Wildfire Smoke Prompt Push for More Monitoring
When the catastrophic Los Angeles fires broke out, John Volckens suspected firefighters and residents were breathing toxic air from the burning homes, buildings, and cars, but it was unclear how much risk the public faced. So, the professor of environmental health at Colorado State University devised a plan to get answers. Volckens shipped 10 air…
Home Care Interoperability Partnerships Drive Continuity of Care
Pennant Group CIO Bryant Saxon describes benefits of building integrations with Scripps Health, John Muir Health and Hartford Healthcare
Solu Therapeutics Lands $41M for Clinical Test of Novel Antibody Drug for Blood Cancer
Solu Therapeutics’ platform technology, which was licensed from GSK, pairs a small molecule with an antibody to address elusive disease targets. Cancer is Solu’s initial focus, but the startup is also exploring applications of its platform to immunology. The post Solu Therapeutics Lands $41M for Clinical Test of Novel Antibody Drug for Blood Cancer appeared…
Vertex Cell Therapy Misses in the Clinic, But It Has Other Shots on the Type 1 Diabetes Goal
Vertex Pharmaceuticals is stopping development of VX-264, an experimental cell therapy/medical device treatment for type 1 diabetes, after an early look at Phase 1/2 data fell short of efficacy goals. This program came from a $950 million acquisition in 2019 that marked Vertex’s entry into type 1 diabetes. The post Vertex Cell Therapy Misses in…
J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies
Johnson & Johnson’s agreement to acquire Intra-Cellular Therapies brings Caplyta, which is projected to become a blockbuster seller across several neurological indications. In other M&A news, GSK and Eli Lilly each struck deals to fill their cancer drug pipelines. The post J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies appeared…
How AI is Accelerating the Need for Real World Data in Healthcare and Life Sciences
Considering the lack of high quality data, companies that excel in compiling and managing data effectively are attracting interest from industry partners and distinguishing themselves from their rivals. Here are some of the ways emerging AI applications are fueling and redefining the need for RWD across HCLS. The post How AI is Accelerating the Need…
Powered by People Rooted in Purpose—The 2nd Annual EVS Conference
Powered by People Rooted in Purpose The 2nd Annual Northeast Division Conference & Trade Show was a resounding success, bringing together more than 250 Environmental Services (EVS) leaders, industry vendors, and guest speakers for an event focused on best practices, innovation, and the future of EVS. The trade show was planned and led by the…
Free Market Health Acquires Beeline Rx to Streamline Specialty Prior Auth
Free Market Health acquired Beeline Rx, a tech company that streamlines the prior authorization process for specialty drugs. The post Free Market Health Acquires Beeline Rx to Streamline Specialty Prior Auth appeared first on MedCity News.